Premium
Verruciform Xanthoma in Severe Phenytoin‐Induced Gingival Overgrowth: A Case Report
Author(s) -
ElKaissi AbdelMagid N.
Publication year - 2014
Publication title -
clinical advances in periodontics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.182
H-Index - 2
eISSN - 2163-0097
pISSN - 2573-8046
DOI - 10.1902/cap.2012.120107
Subject(s) - phenytoin , medicine , lesion , malignancy , dermatology , hyperplasia , differential diagnosis , biopsy , pathogenesis , pathology , epilepsy , psychiatry
Phenytoin is involved in drug‐induced gingival overgrowth (GO), with a prevalence rate reaching 50%. In the literature, tumorigenic implication has been discussed with this form of hyperplasia with considerable controversy. To the author's knowledge, this is the first report since 1971 of a combined phenytoin‐induced hyperplasia with verruciform xanthoma (VX). The importance of differentiating this lesion from classic hyperplasia is emphasized in this case report. Case Presentation: A 23‐year‐old male presented with an advanced case of GO attributable to prolonged intake of phenytoin. Oral examination showed total coverage of the dentition, with one unusual cauliflower‐like lesion. Surgery was performed and a biopsy was taken. Histopathologic examination revealed the diagnosis of VX. No recurrence of the disease was evident 12 months after therapy. Conclusions: The definitive pathogenesis of GO and VX is under discussion and some similarities and possible immunologic interactions that might determine the correct sequence of events can be found. The most relevant differential diagnosis of VX is squamous cell carcinoma, which needs to be detected as early as possible. Although no malignancy was found in this case, VX could be a potentially premalignant lesion.